249 related articles for article (PubMed ID: 29158148)
1. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
Mowla A; Modarresi F; Dastgheib SA
Asian J Psychiatr; 2018 Dec; 38():92-95. PubMed ID: 29158148
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
3. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
[TBL] [Abstract][Full Text] [Related]
4. Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial.
Mowla A; Baniasadipour H
Int Clin Psychopharmacol; 2023 Jan; 38(1):4-8. PubMed ID: 35695582
[TBL] [Abstract][Full Text] [Related]
5. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
[TBL] [Abstract][Full Text] [Related]
6. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
8. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
10. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder.
Sousa MB; Isolan LR; Oliveira RR; Manfro GG; Cordioli AV
J Clin Psychiatry; 2006 Jul; 67(7):1133-9. PubMed ID: 16889458
[TBL] [Abstract][Full Text] [Related]
12. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
March JS; Biederman J; Wolkow R; Safferman A; Mardekian J; Cook EH; Cutler NR; Dominguez R; Ferguson J; Muller B; Riesenberg R; Rosenthal M; Sallee FR; Wagner KD; Steiner H
JAMA; 1998 Nov; 280(20):1752-6. PubMed ID: 9842950
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
14. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
Greist JH; Jefferson JW; Kobak KA; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowtiz MR; Lydiard B
Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
[TBL] [Abstract][Full Text] [Related]
16. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
Rasmussen S; Hackett E; DuBoff E; Greist J; Halaris A; Koran LM; Liebowitz M; Lydiard RB; McElroy S; Mendels J; O'Connor K
Int Clin Psychopharmacol; 1997 Nov; 12(6):309-16. PubMed ID: 9547132
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
[TBL] [Abstract][Full Text] [Related]
18. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder.
Fineberg NA; Baldwin DS; Drummond LM; Wyatt S; Hanson J; Gopi S; Kaur S; Reid J; Marwah V; Sachdev RA; Pampaloni I; Shahper S; Varlakova Y; Mpavaenda D; Manson C; O'Leary C; Irvine K; Monji-Patel D; Shodunke A; Dyer T; Dymond A; Barton G; Wellsted D
Int Clin Psychopharmacol; 2018 Nov; 33(6):334-348. PubMed ID: 30113928
[TBL] [Abstract][Full Text] [Related]
19. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
